Lotte Holdings Healthcare & Biopharmaceutical CVC Invests in Rakuten Medical, Inc.
NQ Score
82/100
AI Summary (NQ-processed)
Lotte Holdings, through its Healthcare & Biopharmaceutical Corporate Venture Capital (HB-CVC), has invested in Rakuten Medical, Inc., marking its eighth HB-CVC investment.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What is the purpose of Lotte Holdings' investment in Rakuten Medical?
- A: The purpose is to expand business in the healthcare and biopharmaceutical sectors, contribute to innovative cancer treatment technologies, and create business synergies through manufacturing contracts with Lotte Biologics.
- Q: What kind of treatment is "photoimmunotherapy" developed by Rakuten Medical?
- A: It is a treatment method that combines drugs and light, where light-activated drugs selectively destroy cancer cells. It uses a drug that combines specific antibodies with a photosensitizer.
- Q: What role will Lotte Biologics play in this partnership?
- A: Lotte Biologics will be responsible for manufacturing some of Rakuten Medical's products, supporting global clinical development and future commercial supply from its Syracuse, USA facility and new plant in Songdo, Korea.